GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GSK’s fourth-quarter Vaccine sales declined 12% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £158 million during the quarter, down 69% year ...

Breakthrough Adjuvant AB-801 Secures“Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) ...

Between being a radio show host, a lead singer in a touring band, and an avid horseback rider, TV personality Faith Martin is living her best life. There's little downtime in Martin's active day ...

The global varicella vaccines market is set for consistent growth, with revenue expected to reach USD 3,258.6 million in 2024 and expand at a CAGR of 2.4% through 2034, ultimately reaching USD 4,115.4 ...

GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal Foreseeing similar difficulties in rolling out these pay-out-of-pocket vaccines, GSK recently also ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

particularly with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company focuses on expanding adult immunization in India. GlaxoSmithKline Pharmaceuticals Limited is a ...

During this conference where the launch of the "Shingrix" vaccine was announced, Engineer Hassan Fahmi General Manager of GSK Egypt, spoke about the importance of introducing the "Shingrix ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the BSE.